盟科药业(688373) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 33,016,131.56, representing a year-on-year increase of 91.10%[5] - The net profit attributable to shareholders was a loss of CNY 102,136,623.67, with a significant increase in losses compared to the previous year[5] - Total operating revenue for Q1 2024 reached ¥33,016,131.56, a significant increase of 91.0% compared to ¥17,276,928.37 in Q1 2023[16] - Net loss for Q1 2024 was ¥102,136,623.67, compared to a net loss of ¥56,162,215.81 in Q1 2023, reflecting a deterioration in performance[17] - Total comprehensive income for Q1 2024 was -¥101,462,981.24, compared to -¥60,536,884.08 in Q1 2023, indicating increased losses[18] Research and Development - R&D expenses totaled CNY 84,646,910.43, accounting for 256.38% of operating revenue, an increase of 4.78 percentage points year-on-year[6] - Research and development expenses increased to ¥84,646,910.43 in Q1 2024, up 94.9% from ¥43,468,902.65 in Q1 2023[16] - The company is currently in a loss-making state due to high R&D and commercialization expenditures as multiple innovative drugs are in critical clinical trial phases[9] Cash Flow and Liquidity - The net cash flow from operating activities was a negative CNY 100,732,791.79, reflecting a decrease in cash flow compared to the previous year[5] - Cash flow from operating activities showed a net outflow of ¥100,732,791.79 in Q1 2024, worsening from a net outflow of ¥52,110,741.31 in Q1 2023[22] - The net cash flow from financing activities was $23,057,563.95, compared to a negative cash flow of $8,706,496.12 in the previous period[23] - The total cash and cash equivalents at the end of the period increased to $216,661,647.43, up from $159,098,146.72 in the previous period[23] - The company reported a cash increase of $79,184,994.28 during the period, compared to an increase of $8,011,306.19 previously[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,103,184,994.54, down 5.59% from the end of the previous year[6] - As of March 31, 2024, the total assets amounted to CNY 1,103,184,994.54, a decrease from CNY 1,168,564,953.55 as of December 31, 2023, reflecting a decline of approximately 5.58%[12] - The company's total liabilities reached CNY 361,374,832.16, up from CNY 334,561,760.77, which is an increase of approximately 8.00%[14] - The long-term borrowings increased significantly to CNY 142,960,000.00 from CNY 114,960,000.00, marking an increase of about 24.39%[14] - The total current liabilities rose slightly to CNY 137,975,631.81 from CNY 136,647,942.77, indicating an increase of approximately 0.97%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 13,542, indicating a stable shareholder base[10] - The company reported a total of 10,151,445 shares held by Shanghai Bai'ao Wealth Medical Investment Partnership, indicating significant shareholder engagement[11] - The company has not reported any participation in margin financing or securities lending by the top shareholders, indicating a stable shareholder structure[12] Government Support - The company received government subsidies amounting to CNY 184,777.34 during the reporting period, which are expected to have a lasting impact on its financial performance[7] Other Financial Metrics - The weighted average return on net assets was -12.96%, a decrease of 8.23 percentage points compared to the same period last year[6] - Basic and diluted earnings per share for Q1 2024 were both -¥0.16, compared to -¥0.09 in Q1 2023[18] - Other comprehensive income after tax for Q1 2024 was ¥673,642.43, a recovery from a loss of -¥4,374,668.27 in Q1 2023[17] - Cash inflow from investment activities was ¥646,070,755.08 in Q1 2024, down from ¥1,007,024,951.62 in Q1 2023[22] - Cash outflow for investment activities was ¥488,237,950.99 in Q1 2024, compared to ¥936,466,469.01 in Q1 2023[22] Management - The company is led by Zhengyu Yuan, with Li Zhile serving as the head of accounting[23]